Highlights Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
0.5056 ^USD	-0.47%		+9.56%	-29.78%

Jun. 10	Oppenheimer Adjusts Price Target on Galecto to $9 From $10, Maintains Outperform Rating	MT
May. 01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	May. 01	CI
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	Dec. 21	CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23-10-23	CI
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	23-08-15	CI
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Earnings Flash (GLTO) GALECTO Posts Q3 Loss $-0.54	22-11-08	MT
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022	22-10-31	CI
Galecto Enters Collaboration for Cancer Drug Study in Portland	22-10-19	MT
Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute	22-10-19	CI
Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis	22-09-29	CI
Galecto, Inc. Positive Results from A Planned Intermediate Assessment of Its Ongoing Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	22-09-29	CI
Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal	22-08-29	CI
Earnings Flash (GLTO) GALECTO Posts Q2 Loss $-0.67	22-07-29	MT
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Galecto, Inc.

Equities

GLTO

US36322Q1076

Highlights

Filters